Listing Agreements Drugs

Reimbursement criteria may be published in the form as therapeutic indications and it is the responsibility of the prescribing physician to prescribe the drug to ODB receptors according to the listed criteria. Product listing agreements allow ODB receptors to access new drugs, while information that could support a more detailed list will be collected and verified. Product listing agreements (PDOs) between drug manufacturers and pharmaceutical plans are becoming more common around the world. The use of ASA by Canadian provinces has not yet been documented. People who buy drugs themselves – which a very large number of Canadians still have to do – do not benefit from these lower prices. In the absence of public data sources, we requested information on the use of the People`s Liberation Army directly from policymakers in each province. Due to the sensitivity of the ASA information, we first consulted with policymakers to determine what information could and could not be made public. In May 2012, we asked policymakers if they could disclose specific information on PLA coverage, consumption and PLA type (e.g. B simple discounts, price-volume agreements or results-based pricing). After collecting information and feedback from the 10 provinces, in July 2012 we requested information for each drug for a sample of drugs that received a first CoR (Common Drug Review) recommendation in 2010 or 2011 and were then funded in one or more provinces.

A total of 35 drugs were first verified by the RDC in 2010-2011. We excluded nine of these drugs because they were not covered by any province as of May 2012 – and therefore would not generate data on PDOs. We also excluded one drug, Janumet, because confidentiality clauses regarding related PDOs in some anonymous provinces would necessarily limit participation in our study. Policymakers indicated that provinces are not able to provide details on the specific conditions of each Pla, as they are confidential. We therefore limited ourselves to documenting only the presence of a PLA for each drug, but not the type of PLA used. Table 11 lists, for each province, the total number of drugs in our sample that were funded and the total number for which there was an PLA (the full results of drug coverage and PLA use by each province are available in Appendix 1 [available online under]. .